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Abstract 23 
The food industry is moving towards the use of natural sweeteners such as those produced by 24 
Stevia rebaudiana due to the number of health and safety concerns surrounding artificial 25 
sweeteners. Despite the fact that these sweeteners are natural; they cannot be assumed safe. 26 
Steviol glycosides have a steroidal structure and therefore may have the potential to act as an 27 
endocrine disruptor in the body. Reporter gene assays (RGAs), H295R steroidogenesis assay 28 
and Ca2+ fluorimetry based assays using human sperm cells have been used to assess the 29 
endocrine disrupting potential of two steviol glycosides: stevioside and rebaudioside A, and 30 
their metabolite steviol. A decrease in transcriptional activity of the progestagen receptor was 31 
seen following treatment with 25,000 ng/ml steviol in the presence of progesterone (157 32 
ng/ml) resulting in a 31% decrease in progestagen response (p= <0.01). At the level of 33 
steroidogenesis, the metabolite steviol (500-25,000 ng/ml) increased progesterone production 34 
significantly by 2.3 fold when exposed to 10,000 ng/ml (p= <0.05) and 5 fold when exposed 35 
to 25,000 ng/ml (p=<0.001). Additionally, steviol was found to induce an agonistic response 36 
on CatSper, a progesterone receptor of sperm, causing a rapid influx of Ca2+. The response 37 
was fully inhibited using a specific CatSper inhibitor. These findings highlight the potential 38 
for steviol to act as a potential endocrine disruptor.  39 
Key terms: Endocrine disruptors, in vitro bioassays, steviol, reproductive disorders, CatSper; 40 
Stevia 41 
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1. Introduction  46 
Steviol glycosides are high intensity sweeteners that can be isolated and purified from the 47 
leaves of Stevia rebaudiana (Bertoni). These glycosides of the diterpene derivative steviol 48 
consist mainly of stevioside and rebaudioside A. These chemicals have sweetening potentials 49 
200-300 times that of sucrose, are thermally stable and account for approximately 5-10% of 50 
dry leaf weight (Soejarto, et al., 1982). 51 
The increasing prevalence of diabetes and obesity worldwide, in conjunction with a growing 52 
concern over the safety of chemical sweeteners such as aspartame has led to a growing 53 
demand for natural non-calorie sweeteners such as steviol glycosides which are presumed 54 
safe to eat and are of acceptable taste. With increasing health consciousness, the use of 55 
steviol glycosides as a food additive is now encouraged to slow down the world-wide sugar 56 
consumption and therefore contribute towards combating the increasing diabetes and obesity 57 
rates (Brahmachari, et al., 2011). Steviol glycosides are now authorised for use in a range of 58 
commonly consumed food products (The European Commission, 2011), resulting in steviol 59 
equivalents within a range of 20,000 up to 3,300,000 ng/ml abundantly present in foods 60 
(Table 1). 61 
 62 
 63 
 64 
 65 
 66 
 67 
 68 
Table 1: Examples of authorised uses of steviol glycosides (E-Number 960, expressed as 69 
steviol equivalents) in food. 70 
 71 
The safety of steviol glycosides for the proposed use as food additives has been evaluated by 72 
the Joint Expert Committee on Food Additives (JECFA), a scientific advisory body of Food 73 
and Agriculture Organization (FAO) of the United Nations, and the World Health 74 
Organisation (WHO). JECFA have established an ADI (Acceptable Daily Intake) for steviol 75 
glycosides (expressed as steviol equivalents) of 4 mg/kg bw/day (FAO, 2010). This ADI 76 
takes into account a no-observed-adverse-effect-level (NOAEL) and applies a 100-fold safety 77 
uncertainty factor extrapolated from a 2-year carcinogenicity study on rats consuming 2.5% 78 
stevioside in the diet, equating to 967 mg stevioside/kg bw/day or 388 mg steviol 79 
Food category 
Maximum level 
steviol 
equivalents 
(ng/ml or ng/g ) 
Restrictions/Exceptions 
Cocoa and Chocolate 
products; 
as covered by Directive 
2000/36/EC 
270,000 
Only energy-reduced or with no 
added sugars 
Chewing gum 3,300,000 Only with no added sugar 
Flavoured Drinks 80,000 
Only energy reduced or with no 
added sugar 
Potato – cereal, flour or 
starch-based snacks 
20,000  
Jam, Jellies and marmalades 
and sweetened chestnut 
puree; 
as defined by Directive 
2001/113/EC 
200,000 
Only energy-reduced jams, jellies 
and marmalades 
Fruit and vegetables 
(preparations excluding 
compote) 
200,000 Only energy-reduced 
equivalents/kg bw/day (Xili et.al., 1992). However, conservative estimates of steviol 80 
glycoside exposure, both in adults and in children, suggest that the ADI would in some cases 81 
be exceeded at the maximum proposed use levels (The European Commission, 2011). 82 
Consumption studies demonstrate that intact steviol glycosides are poorly absorbed by 83 
humans after oral exposure (Pawar, et al., 2013). However, they may be hydrolysed to the 84 
metabolite steviol by intestinal microflora in the colon, where the majority is absorbed across 85 
the gut wall and the rest is excreted in the faeces. To aid excretion from the body, absorbed 86 
steviol is rapidly transformed to steviol glucuronide in the liver via conjugation to an acyl-87 
glucuronide (Brusick, 2008). Consequently, while steviol glycosides and steviol are not 88 
detected in the blood or urine of human subjects, steviol glucuronide has been reported in 89 
urine and steviol in faeces (Wheeler, et al., 2008).  90 
Human studies into “safe” levels of steviol glycoside consumption have shown that daily 91 
doses of rebaudioside A up to 1,000,000 ng/person/day were well-tolerated by individuals 92 
with type-2 diabetes mellitus or normal glucose metabolism (Maki et al., 2008). This dose 93 
equates to approximately 16,600 ng/kg bw/day for a 60 kg person and corresponds to 94 
approximately 330,000 ng steviol equivalents/person/day or to 5,500 ng steviol 95 
equivalents/kg bw/day (Maki et al., 2008).  96 
Steviol glycosides and steviol possess a steroidal structure (Fig.1) and therefore may have the 97 
potential to act as an endocrine disrupting chemical (EDC).  98 
Figure 1: Chemical structure of steviol, stevioside and rebaudioside A 99 
The WHO defines an EDC as “an exogenous substance or mixture that alters function(s) of 100 
the endocrine system and consequently causes adverse health effects in an intact organism, or 101 
its progeny, or (sub)populations” (WHO, 2002). It is now known that EDCs can act via 102 
multiple mechanisms within the cell and body. These mechanisms may include the 103 
mimicking or blocking of transcriptional activation elicited by naturally present hormones via 104 
binding to hormone receptors or interference with hormone production, secretion and control 105 
systems in the steroidogenesis pathway (Tabb and Blumberg, 2005).  106 
A limited number of studies have been presented to date on the effects of steviol glycosides 107 
on the endocrine system. Some studies conversely report no adverse effects on the 108 
reproduction, organs, sperm or foetal development of male or female rats (EFSA, 2010). The 109 
majority of these studies have used Stevia rebaudiana extracts as opposed to the pure steviol 110 
glycosides.  111 
In vitro bioassays are extremely useful tools for the detection and mechanistic study of EDCs 112 
(Connolly et al., 2011). The current study aims to investigate the endocrine disrupting 113 
activity of the natural sweeteners stevioside and rebaudioside A and their metabolite steviol. 114 
Mammalian reporter gene assays (RGAs) incorporating natural steroid receptors have been 115 
used to assess effects on nuclear receptor transcriptional activity (Willemsen et al., 2004), 116 
while the H295R human adrenal carcinoma cell line which has all the important enzymes and 117 
genes needed for steroidogenesis has been used as a model to study effects on hormone 118 
production (Hecker and Giesy, 2008). Ca2+ fluorimetry based assays using human sperm 119 
cells, have also been used to assess the effects of EDCs on the Ca2+ channel of sperm 120 
(CatSper), which has progesterone as its natural ligand (Schiffer et. al., 2014; Tavares et.al., 121 
2013). CatSper regulates several important sperm functions and is absolutely required for 122 
male fertility (Smith et.al., 2013).  123 
To the best of our knowledge this is the first reported study investigating the endocrine 124 
disrupting potential of the natural sweeteners stevioside and rebaudioside A and their 125 
metabolite steviol at the level of nuclear receptor transcriptional activity using oestrogen, 126 
androgen, progestagen and glucocorticoid RGAs, on steroidogenesis using the H295R 127 
steroidogenesis model and on the non-genomic progesterone receptor of sperm, CatSper. 128 
2. Methods 129 
2.1 Chemicals and reagents 130 
Cell culture reagents were supplied by Life Technologies (Paisley, UK). The standards 17β-131 
oestradiol, testosterone, hydrocortisone, progesterone, steviol, stevioside, rebaudioside A and 132 
forskolin were obtained from Sigma-Aldrich (Poole, Dorset, UK). Dimethyl sulfoxide 133 
(DMSO) and thiazolyl blue tetrazolium bromide (MTT) were also supplied by Sigma-134 
Aldrich. Lysis reagents and luciferase assay system was purchased from Promega 135 
(Southampton, UK). Fluorescent Ca2+ indicator Fluo-4 was provided by Invitrogen (USA). 136 
MDL12330A was supplied by Tocris (USA). Human serum albumin was purchased from 137 
Irvine Scientific (USA). 138 
2.2 Cell culture 139 
Four reporter gene assay (RGA) cell lines, the MMV-Luc (oestrogen responsive), TARM-140 
Luc (androgen and progestagen responsive), TM-Luc (progestagen responsive) and TGRM-141 
Luc (glucocorticoid and progestagen responsive) were previously developed by transforming 142 
human mammary gland cell lines with the luciferase gene under the control of a steroid 143 
hormone inducible promoter (Willemsen et al., 2004). The H295R human adrenocortical 144 
carcinoma cell line, used in the steroidogenesis model, was obtained from the American Type 145 
Culture Collection (ATCC CRL-2128, Manassas, VA, USA).  146 
All cell lines were routinely grown in 75 cm2 tissue culture flasks (Nunc, Roskilde, Denmark) 147 
at 37°C with 5% CO2 and 95% humidity. The RGA cell lines were cultured in cell culture 148 
medium containing Dulbecco’s Modified Eagle Medium (DMEM), 10% foetal bovine serum 149 
and 1% penicillin streptomycin. For culturing the MMV-Luc cell line, DMEM without 150 
phenol red was used due to the weak oestrogenicity of phenol red. The H295R cell line was 151 
cultured in cell culture medium containing DMEM with Ham’s F-12 nutrient mixture (1:1) 152 
supplemented with 1% ITS + Premix and 2.5% NuSerum (BD Biosciences, Bedford, MA, 153 
US).  154 
2.3 Cell viability assays 155 
2.3.1 MTT assay 156 
The MTT assay was performed to monitor the toxic effects of test compounds in the RGA 157 
cell lines. Briefly, clear flat-bottomed 96-well plates (Nunc, Roskilde, Denmark) were seeded 158 
with 4 x 105 cells/ml of the appropriate cell line. After 24 h stevioside and steviol (500, 1,000, 159 
5,000, 10,000 and 25,000 ng/ml) and rebaudioside A (5,000, 10,000, 25,000, 50,000 and 160 
100,000 ng/ml) were added to the cells at a final DMSO concentration of 0.1%. Test 161 
compounds were then incubated for a further 48 h. Viable cells convert the soluble yellow 162 
MTT into insoluble purple formazan by the action of mitochondrial succinate dehydrogenase. 163 
Following incubation, supernatant was discarded and 50 µl of MTT solution/well (5mg/ml 164 
stock in PBS diluted in 1:2.5 in assay media) was added and cells were incubated for a further 165 
3 h. The supernatant was removed and 200 µl of DMSO was added to each well and 166 
incubated for a further 10 min with agitation at 37°C to dissolve the formazan crystals. 167 
Optical density was measured using a Sunrise spectrophotometer at 570 nm with a reference 168 
filter at 630 nm (TECAN, Switzerland). Samples were analysed in triplicate wells and in 169 
three independent experiments. Viability was calculated as a percentage absorbance of the 170 
sample when compared with the absorbance of the DMSO solvent control.  171 
2.3.2 AlamarBlue® assay 172 
The viability of the H295R cells was determined using the AlamarBlue® assay. After the 173 
removal of the media for hormone analysis, 1 ml of 1:10 (v:v) AlamarBlue® in cell culture 174 
medium was added to each well and incubated for 6 h. A 100 µl volume was then removed 175 
from each well and added into clear flat-bottomed 96-well microtitre plates (Nunc, Roskilde, 176 
Denmark). Using a Sunrise spectrophotometer (TECAN, Switzerland) the absorbance was 177 
measured at 570 nm and 600 nm. Viability was calculated as the % absorbance of the sample 178 
in comparison with the absorbance of the solvent control (0.1%, v:v DMSO in media). 179 
2.4 Reporter gene assays (RGAs) 180 
The RGA procedure has previously been described by Frizzell et al., (2011). Briefly, cells 181 
were seeded at a concentration of 4 × 105 cells/ml, 100 ml/well in specialised white walled, 182 
clear and flat bottomed 96-well plates (Greiner Bio-One, Fricken- hausen, Germany). After 183 
24 h, stevioside, steviol (500, 1,000, 5,000, 10,000 and 25,000 ng/ml), rebaudioside A (5,000, 184 
10,000, 25,000, 50,000 and 100,000 ng/ml) and the steroid hormone standards were added to 185 
the cells at a final DMSO concentration of 0.1%. The positive controls used with their 186 
respective cell lines were: 1.36 ng/ml 17β-oestradiol (MMV-Luc), 14.5 ng/ml testosterone 187 
(TARM-Luc), 157 ng/ml progesterone (TM-Luc) and 181 ng/ml hydrocortisone (TGRM-188 
Luc). A solvent control (0.1%, v:v DMSO in media) was also included for each cell line. 189 
Antagonist tests were carried out by incubating the test compounds with the relevant positive 190 
control for the cell line being tested. The cells were incubated for 48 h. The supernatant was 191 
discarded and the cells washed once with PBS prior to lysis with 20 µl cell lysis buffer 192 
(Promega, Southampton, UK). Finally, 100 µl luciferase substrate (Promega, Southampton, 193 
UK) was injected into each well and luciferase activity measured using a Mithras Multimode 194 
Reader (Berthold, Other, Germany). RGAs were performed in triplicate for each 195 
experimental point and repeated in at least two independent exposures. The response of the 196 
cell lines to the various compounds was measured and compared with the solvent and 197 
positive controls. 198 
2.5 Steroidogenesis assay 199 
As steviol glycosides are metabolised to steviol in vivo, steviol was tested at five different 200 
concentrations (500, 1,000, 5,000, 10,000 and 25,000 ng/ml). The highest soluble 201 
concentration achieved in DMSO was 25,000 ng/ml. The H295R assay was performed as 202 
described previously (Gracia et al., 2007). Briefly, the cells were seeded at a concentration of 203 
3 × 105 cells/ml, 1 ml per well, in 24-well plates (BD Biosciences, Bedford, MA, US). The 204 
cells were allowed to attach for 24 h before removing the media and replacing with fresh 205 
media containing the test compounds dissolved in DMSO at a final concentration of 0.1% 206 
(v:v). Forskolin was used as a positive control at a concentration of 10uM. A solvent control 207 
(0.1%, v:v DMSO in media) was also included. Subsequently, the media was collected from 208 
the wells following 48 h incubation and stored at −20°C until hormone quantification was 209 
carried out. A 48 hour incubation time allows the concentrations of these hormones to reach a 210 
plateau-phase under these conditions. The AlamarBlue® cell viability assay was carried out 211 
on the remaining cells in each well. Each experimental point was performed in triplicate in at 212 
least two independent exposures. 213 
2.6 Hormone detection and quantification 214 
Frozen media was thawed prior to analysis. Oestradiol, testosterone and progesterone levels 215 
in the media were quantified by enzyme-linked immunosorbent assays (ELISAs) 216 
(Immunodiagnostics, Marburg, Germany). These highly specific kits are based on the 217 
principle of competitive binding and are intended for the quantitative in vitro diagnostic 218 
measurement of oestradiol (0–2000 pg/ml), testosterone (0–16 ng/ml) and progesterone (0–40 219 
ng/ml) in serum and plasma, with sensitivities of 9.714 pg/ml, 0.083 ng/ml and 0.045 ng/ml 220 
respectively. ELISA kits were carried out according to manufacturer’s instructions with the 221 
exception of the standard curves which were prepared in the same culture medium used for 222 
the H295R assay. Prior to media analysis, it was confirmed that steviol (500-25,000 ng/ml) 223 
did not cross-react with the progesterone ELISA antibody (data not included). The intra-assay 224 
coefficient of variation was less than 10%. Standard curves were included on each ELISA 225 
plate. The mean absorbance obtained from each standard was plotted against its concentration 226 
using dose–response curves generated with Graph Pad Prism software. 227 
2.7 Sperm preparation and measurement of changes in intracellular Ca2+ 228 
concentration 229 
Samples of human semen were obtained from healthy volunteers with their prior consent. 230 
Sperm were prepared as described (Schiffer et.al., 2014). Briefly, sperm were purified by a 231 
“swim-up” procedure in human tubular fluid (HTF+) containing (in mM): 97.8 NaCl, 4.69 232 
KCl, 0.2 MgSO4, 0.37 KH2PO4, 2.04 CaCl2, 0.33 Na-pyruvate, 21.4 lactic acid, 2.78 glucose, 233 
21 HEPES, and 4 NaHCO3 adjusted between pH 7.3-7.4 with NaOH. After washing, human 234 
serum albumin (3 mg/ml) was added to HTF+. Sperm were incubated for at least 1 h in HTF+ 235 
with 3 mg/ml serum albumin at 37 °C in a 10% CO2 atmosphere. 236 
Changes in intracellular Ca2+ concentration in human sperm were measured in 384 multi-well 237 
plates in a fluorescence plate reader (Fluostar Omega, BMG Labtech, Germany) at 30 °C. 238 
Sperm were loaded with the fluorescent Ca2+ indicator Fluo-4 (10 μM) for 45 min at 37 °C. 239 
After incubation, excess dye was removed by centrifugation (700 x g, 10 min, RT). The 240 
sperm pellet was resuspended in HTF+ to 5 × 106 sperm/ml. Aliquots of 50 μl were loaded to 241 
the wells of the multi-well plate. Fluorescence was excited at 480 nm and emission was 242 
recorded at 520 nm with bottom optics. Fluorescence was recorded before and after injection 243 
of 25 μl (1:3 dilution) of negative control (buffer), positive control (progesterone, 5 µM) and 244 
steviol manually with an electronic multichannel pipette. Steviol was dissolved in DMSO to 245 
10 mM and further diluted in HTF+. Changes in Fluo-4 fluorescence are shown as ΔF/F0 (%), 246 
indicating the percentage change in fluorescence (ΔF) with respect to the mean basal 247 
fluorescence (F0) before addition of steviol, positive control and negative control. For the 248 
inhibition experiment, sperm were incubated with MDL12330A for 5 min prior to addition of 249 
steviol. 250 
2.8 Statistical Analysis 251 
All values shown are expressed as mean ± standard deviation (SD) of at least two 252 
independent exposures for the compounds tested (for two independent exposures n=2 and for 253 
three independent exposures n=3). Data from the cell viability, reporter gene, steroidogenesis 254 
and Ca2+ fluorimetry assays were analysed using Microsoft Excel and Graphpad PRISM 5 255 
software (San Diego, CA). A one way analysis of variance (ANOVA) and Dunnett’s Multiple 256 
Comparison Test was used to determine significant differences between treatments and the 257 
corresponding controls. The mean concentrations were tested for significant difference at the 258 
95% confidence level, a P-value of <0.05 was considered as significant (P≤0.05 *, P≤0.01 ** 259 
and P≤0.001 ***). 260 
 261 
3 Results 262 
3.1 Cell viability and cytotoxicity 263 
Stevioside (500-25,000 ng/ml), steviol (500-25,000 ng/ml) and rebaudioside A (5000-264 
100,000 ng/ml) were assessed for cytotoxicity by the MTT assay in the MMV-Luc (oestrogen 265 
responsive), TM-Luc (progestagen responsive), TARM-Luc (androgen and progestagen 266 
responsive) and TGRM-Luc (glucocorticoid and progestagen responsive) cell lines (Fig.2). 267 
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Cytotoxicity was observed at the higher concentrations of stevioside in the TARM-Luc 268 
(25,000 ng/ml p ≤ 0.001), TM-Luc (5,000, 10,000, and 25,000 ng/ml, P ≤ 0.001) and TGRM-269 
Luc (10,000 and 25,000 ng/ml, P ≤ 0.001) RGA cell lines. 270 
Steviol (500-25,000 ng/ml) was assessed for cytotoxicity in the H295R cell line by the 271 
AlamarBlue® assay. Cytotoxicity was not observed at any of the concentrations tested (data 272 
not shown). The viability of the cells at the sample concentrations did not differ significantly 273 
from the DMSO solvent control (P ≥0.05).  274 
 275 
 276 
  277 
 278 
 279 
 280 
 281 
Figure 2: Viability of the RGA cell lines following exposure to (a) 500-25,000 ng/ml 282 
stevioside for 48 h compared to the solvent control, as determined in the MTT assay. The 283 
MMV-Luc cell line is specific for the detection of oestrogens, TARM-Luc for androgens and 284 
progestagens, TM-Luc for progestagens and TGRM-Luc for glucocorticoids and 285 
progestagens. Values are means ± SD for three independent exposures in triplicate (n = 3). P 286 
= <0.05 (*) P≤ 0.01 (**) P = <0.001 (***) 287 
3.2 Reporter gene assay 288 
Po
sit
iv
e 
co
nt
ro
l
50
0
10
00
50
00
10
00
0
25
00
0
0
20
40
60
80
100
120
140
**
Steviol (ng/ml)
R
e
la
ti
ve
 R
e
sp
o
n
se
 (
%
)
An agonist response was not observed for stevioside, steviol or rebaudioside A in the MMV-289 
Luc, TM-Luc, TARM-Luc or TGRM-Luc cell lines (data not shown). Additionally, no 290 
antagonist response was seen for stevioside and rebaudioside A in the MMV-Luc, TM-Luc, 291 
TARM-Luc or TGRM-Luc cell lines (data not shown). Steviol appeared to exhibit an 292 
antagonist response in the progesterone responsive TM-Luc cell line, with a 28.1% reduction 293 
in progesterone response at the highest concentration of 25,000 ng/ml (P ≤ 0.05) (Fig.3). At 294 
this concentration of steviol, no reduction in cell viability was observed in the MTT assay. 295 
Although there was a trend in reduction of glucocorticoid transcriptional activity at 25,000 296 
ng/ml steviol, this reduction was not significant (P ≥ 0.05). 297 
 298 
 299 
 300 
 301 
 302 
 303 
 304 
Figure 3: Antagonist effects in the TM-Luc cell line cell lines for 500-25,000 ng/ml steviol. 305 
Responses measured are compared to the relative positive control (157 ng/ml progesterone). 306 
Response is expressed as the percentage response ± SD for three independent exposures in 307 
triplicate (n = 3). P = ≤0.01 (**) 308 
3.3 Hormone production results 309 
Steviol did not induce significant changes in the production of oestradiol and testosterone 310 
(data not shown). However, progesterone production increased significantly by 2.3 fold when 311 
exposed to 10,000 ng/ml (P = <0.05) and 5 fold when exposed to 25,000 ng/ml (P =<0.001) 312 
(Fig.4). 313 
 314 
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 322 
Figure 4: Progesterone production by H295R cells following exposure to 500-25,000 ng/ml 323 
steviol for 48 h. Values are means ± SD for three independent exposures in triplicate (n = 3). 324 
P = <0.05 (*) P≤ 0.001 (***). 325 
3.4 Effects on progesterone receptor of sperm, CatSper 326 
Steviol was found to induce Ca2+ signals in human sperm cells (n=5) (Fig. 5a). The induced 327 
response was found to be inhibited 98.65±1.91% by the specific CatSper inhibitor 328 
MDL12330A (n=3) (Fig. 5b). Analysis of the dose-response relation yielded an EC50 of 329 
10.82±1.06 µM/3,446.17±337,61 ng/ml (n=4) (Fig. 5c-d). The EC02 was also calculated 330 
which corresponds to the lowest effective dose of steviol for inducing effects on CatSper, 331 
0.676±0.623 µM/ 215.3 ± 198.4 ng/ml (n=4).  332 
 333 
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 Figure 5 (a-d): (a) Ca2+ signals in human sperm cells induced by steviol, 10 µM, added at 0 366 
s (n=5) (b) Steviol-induced Ca2+ signal in the absence (blue) and presence (red) of the 367 
CatSper inhibitor MDL12330A (c) Steviol-induced Ca2+ signals from one experiment, 368 
included for estimation of steviol dose-response relationship in d). (d) Normalized dose-369 
response relationships of steviol, mean ± SEM (n=4). 370 
4 Discussion  371 
The endocrine disrupting effects of steviol glycosides (stevioside and rebaudioside A) and 372 
their metabolite steviol have been investigated using mammalian in vitro bioassays that are 373 
able to detect endocrine disruption at the level of nuclear receptor transcriptional activity and 374 
steroidogenesis. Additionally, the effect of steviol on the progesterone receptor of sperm, 375 
CatSper, was investigated.  376 
Cell viability assays are useful controls to ensure that the effects seen in the mechanistic 377 
studies are not a result of decreasing cell viability. Cytotoxicity was observed with the higher 378 
concentrations of stevioside in the TARM-Luc (25,000 ng/ml), TM-Luc (5,000, 10,000, and 379 
25,000 ng/ml) and TGRM-Luc (10,000 and 25,000 ng/ml) responsive RGA cell lines. 380 
Interestingly the MMV-Luc cell line did not appear to be affected by concentrations up to 381 
25,000 ng/ml. This observed difference may be due to the fact that the parent cell line of the 382 
TARM-Luc, TM-Luc and TGRM-Luc cell lines is T47D while for MMV-Luc it is MCF-7. A 383 
similar effect was seen in a previous study by Frizzell et al., (2013), where the test 384 
compound, alternariol, reduced cell viability in the three T47D cell lines but with no 385 
reduction in viability in the MMV-Luc cells (Frizzell et.al.,2013). Studies investigating the in 386 
vitro cytotoxicity of stevioside, steviol and rebaudioside A are scarce. However, Ukiya et al., 387 
(2013) investigated the potential cytotoxicity of steviol in breast (SK-BR-3), leukemia 388 
(HL60), lung (A549) and stomach (AZ521) cancer cell lines by means of the MTT assay and 389 
stated that steviol at a concentration of up to 31,845 ng/ml did not induce cytotoxic effects, 390 
therefore in agreement with the present study. In spite of this, Paul et al (2012) showed a 391 
significant decrease from the solvent control at 3,185 ng/ml stevioside with the effects (71% 392 
of cells undergoing apoptosis) being more pronounced 72 h treatments. Additionally, results 393 
from the trypan blue test in this study showed that there was some cytotoxic activity 394 
occurring even at the lowest concentration tested 796 ng/ml. However, the differences in 395 
findings could be due to the fact that in the trypan blue test, cell membrane integrity is 396 
measured rather than mitochondrial membrane integrity as measured by the MTT assay. Also 397 
in the MTT test, stevioside was exposed to the MCF-7 cells for a period of 72 h as opposed to 398 
48 h in the current study. 399 
Reporter gene assays provide specific and biologically relevant ways to screen substances for 400 
their hormonal effects at the level of nuclear receptor transcriptional activity (Willemsen et 401 
al., 2004). The current study revealed no agonist response in any of the RGA cell lines for all 402 
compounds tested, however an antagonist response was observed in the progesterone 403 
responsive TM-Luc cell line whereby 25,000 ng/ml steviol induced a 29.1% decrease in the 404 
progesterone receptor nuclear transcriptional activity. In agreement with these findings, a 405 
study by Oliveira-Filho et.al., (1989) reported that the number of binding sites for androgens 406 
were not altered in rats chronically administered Stevia rebaudiana extract. However, effects 407 
on the androgen receptor have previously been highlighted by Uehara et.al., (1982) who 408 
demonstrated that purified stevioside displaced 5a-dihydrotestosterone specifically bound to 409 
prostate androgen receptors in vitro (Uehara et al., 1982). This finding was confirmed with 410 
the synthetic androgen, methyltrienolone, a specific ligand of androgen receptors (Uehara et 411 
al., 1983). Differences in findings may be due to the varying forms of stevioside used in the 412 
studies i.e. purified or plant extract and also the type of study carried out i.e. in vitro vs in 413 
vivo. 414 
Compounds can also be classed as EDCs through disrupting steroidogenesis; a complex 415 
process regulated by enzymes. Harvey et al., (2007) state that the adrenal gland was often 416 
neglected in regulatory endocrine disruption screening and testing despite it being the most 417 
common toxicological target organ in the endocrine system (Harvey et al., 2007). In the 418 
current study the H295R model was utilised to investigate the effects of steviol on 419 
steroidogenesis. It was observed that steviol had no effect on oestradiol or testosterone 420 
production; however, at 10,000 ng/ml and 25,000 ng/ml, significant increases in the 421 
production of progesterone were observed. Progesterone is an intermediary of oestradiol and 422 
testosterone but the increased progesterone levels observed did not result in a down-stream 423 
increase of oestradiol or testosterone. However, the steroidogenesis pathway is an intricate 424 
and complicated pathway and there may be other events taking place in the pathway that are 425 
affecting the levels of testosterone and oestradiol. In addition, the H295R model has been 426 
validated as an OECD in vitro screening assay to screen for endocrine disruptor action on 427 
oestradiol and testosterone production. The validation process points to 48 hrs as an optimal 428 
time point with the concentrations of these hormones seemingly reaching a plateau-phase 429 
under these conditions and therefore most research to date has been carried out under these 430 
validated conditions. However, further time points, gene and protein expression studies may 431 
reveal additional effects on the levels of oestradiol and testosterone where the intermediary 432 
progesterone is increased.  433 
Steviol was also found to induce an agonistic response on CatSper, the progesterone receptor 434 
of sperm, with an EC50 of 10.82±1.06 µM/3,446.17±337,61 ng/ml and an EC02 of 435 
0.676±0.623 µM/ 215.3 ± 198.4 ng/ml. This response was fully inhibited (98.65±1.91%) 436 
using a specific CatSper inhibitor, indicating that the observed response is indeed mediated 437 
through direct interaction between steviol and CatSper. This is of concern because CatSper 438 
regulates several important sperm functions and is absolutely required for male fertility 439 
(Smith et.al., 2013). Other studies have similiarly shown that structurally diverse chemicals 440 
can act agonistically on CatSper (Schiffer et.al., 2014; Tavares et.al., 2013) and that these 441 
chemicals can act additively in low doses to induce a Ca (2+) response. This hints that even 442 
low doses in the female reproductive tract could possibly affect human sperm cell function, 443 
during their passage through the tract. To our knowledge, steviol has not been measured in 444 
reproductive system fluids. However, due to the close anatomical relationship between the 445 
distal colon/rectum with the reproductive tract in female and seminal vesicles/prostate in 446 
males, it is possible that steviol absorbed in the distal colon/rectum, which bypasses the liver 447 
and portal-circulation, can get into the reproductive fluids (Einer-Jensen and Hunter, 2005). 448 
This study reports that steviol can modulate an increase in progesterone production and 449 
antagonise the progesterone and agonise CatSper receptors. Progesterone plays a major role 450 
in female reproductive health such as maintaining pregnancy, regulating the monthly 451 
menstrual cycle and preparing the body for conception (Healy, 1990). Progesterone receptor 452 
antagonists now have a use in clinical practice both as a contraceptive and in pregnancy 453 
termination (Spitz, 2003). Planas and Kacute (1968) investigated the potential of aqueous 454 
Stevia extract to act as a contraceptive in rats and found that the extract reduced fertility in 455 
adult female rats of proven fertility and fertility continued to decrease for at least 50 to 60 456 
days after intake was stopped (Planas and Kacute, 1968). A link between increased levels of 457 
progesterone and weight gain has been reported (Galletti and Klopper, 1964; Lof et al., 458 
2009). Progesterone also has a significant role in insulin secretion. Insulin has an important 459 
role in controlling blood sugar levels and therefore in patients with diabetes, insulin is either 460 
at very low levels or low functioning. If insulin levels are altered, blood glucose regulation 461 
will be adversely affected and subsequently, diabetes risk could increase (Diabetes UK, 462 
2015). Straub et al., (2001) reported that progesterone had the ability to inhibit glucose-463 
stimulated insulin secretion from isolated rat islets in a dose-dependent manner. However, 464 
further in depth investigations of the relationship between progesterone levels in the body and 465 
glucose-stimulated insulin secretion are required. The results of this study suggest that steviol 466 
could potentially affect glucose and weight homeostasis indirectly through modulation of 467 
steroid hormones. This is of heightened concern due to the fact that steviol glycosides are 468 
non-calorific sweeteners aimed towards reducing the incidence of metabolic disease such as 469 
diabetes and obesity. 470 
A decrease in transcriptional activity of the progesterone receptor was observed following 471 
exposure to 25,000 ng/ml steviol. In the steroidogenesis assay, a significant increase in 472 
progesterone production was found from the lower concentration of 10,000 ng/ml steviol. A 473 
report by EFSA (2011), estimated that exposure to steviol glycosides, expressed as steviol 474 
equivalents, is around 5.6-6.8 mg/kg bw per day (5,600-6,800 ng/ml) for adult high level 475 
consumers in the UK. Additionally, for European children, anticipated exposure of the high 476 
level consumer is estimated to be 1.7-16.3 mg/kg bw per day (1,700-16,300 ng/ml). 477 
Consequently, the levels studied within this investigation are in the range of dietary exposure 478 
levels for children within the high level consumption range. Also, it is possible that as more 479 
products containing the natural sweetener Stevia are developed and sold, exposure levels to 480 
this compound will further increase (Goyal et al., 2009). Stevia will also be of particular 481 
interest to certain groups of the population with metabolic conditions such as diabetes and 482 
obesity and as a result these groups may have an even higher exposure to steviol glycosides. 483 
Therefore, there is an urgent need to ascertain the current level of exposure to steviol 484 
glycosides.  485 
Metabolism studies in humans have reported very low blood levels of free steviol (JECFA, 486 
2005). Steviol glucuronide has been reported to be primarily excreted in urine and steviol in 487 
faeces (Wheeler et al., 2008). As previously outlined, absorbed steviol is rapidly transformed 488 
to steviol glucuronide in the liver via conjugation to an acyl-glucuronide. Consequently, only 489 
absorbed steviol which bypasses the liver and portal-circulation, e.g. absorbed in the distal 490 
colon/rectum, will go unconjugated into general circulation and only until it passes the liver 491 
(Brusick, 2008). Studies have reported that progesterone receptors are present in the epithelial 492 
cells of the colon and progesterone has some effects directly on the gastrointestinal (GI) tract 493 
(Guarino et.al., 2011; Eliakim et.al., 2000). Unconjugated steviol may be present at high 494 
concentrations in the GI tract and may present the potential for steviol to inhibit progesterone 495 
binding to the progesterone receptors. Thereby potentially enabling steviol to disturb 496 
progesterone effects in the GI tract before being conjugated in the liver. It is increasingly 497 
important that current metabolism studies are carried out to assess the metabolic pathways 498 
and effects within the framework of the growing use of stevia glycosides and a widening 499 
range of food products. 500 
Despite the findings of this study, other research on steviol glycosides has concluded that 501 
replacing table sugar or aspartame with these natural sweeteners has various health benefits. 502 
Numerous plant glycosides have shown activity in the prevention of some dietary diseases 503 
including cancer, obesity and diabetes (Bernal et al., 2011). Steviol glycosides are non-504 
caloric and non-cariogenic sweeteners whose consumption may exert beneficial effects on 505 
human health (Gardana et al., 2010).  506 
5 Conclusion 507 
The metabolite of steviol glycosides, steviol, can antagonise the progesterone nuclear 508 
receptor transcriptional activity and increase progesterone production. Additionally, steviol 509 
was found to induce an agonistic response on Catsper, the progesterone receptor of sperm 510 
cells. We have thus shown that steviol has the ability to affect progesterone signalling at three 511 
different sites: 1) By lowering progesterone transcriptional activity 2) by increasing the 512 
production of progesterone and 3) by acting as an agonist on Catsper, the progesterone 513 
receptor of sperm. This study highlights the endocrine disrupting potential of natural 514 
sweeteners such as those found in Stevia rebaudiana and suggests that emerging natural 515 
sweeteners such as Stevia may not be safe alternatives to sugar and other synthetic 516 
sweeteners. Further dietary exposure and metabolic studies are required to confirm their 517 
safety. 518 
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